Vaxcyte, Inc. (PCVX) — Cash & Equivalents
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $173.96M | -55.2% |
| 2024 | $387.88M | -2.4% |
| 2023 | $397.45M | -52.4% |
| 2022 | $834.66M | +1109.9% |
| 2021 | $68.98M | -82.1% |
| 2020 | $386.20M | +554.8% |
| 2019 | $58.98M | — |
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $173.96M | -55.2% |
| 2024 | $387.88M | -2.4% |
| 2023 | $397.45M | -52.4% |
| 2022 | $834.66M | +1109.9% |
| 2021 | $68.98M | -82.1% |
| 2020 | $386.20M | +554.8% |
| 2019 | $58.98M | — |